<DOC>
	<DOCNO>NCT01850641</DOCNO>
	<brief_summary>The purpose study investigate safety efficacy administer PA21 calcium carbonate hemodialysis patient hyperphosphatemia 12 week .</brief_summary>
	<brief_title>A Phase III Study PA21 With Calcium Carbonate Hemodialysis Patients With Hyperphosphatemia</brief_title>
	<detailed_description />
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>Receiving stable maintenance hemodialysis 3 time week Dialysis patient hyperphosphatemia Patients history pronounce brain / cardiovascular disorder Patients severe gastrointestinal disorder Patients severe hepatic disorder</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Hemodialysis</keyword>
	<keyword>Hyperphosphatemia</keyword>
</DOC>